Invivyd Announces Antiviral Activity of VYD222 (pemivibart) Against SARS-CoV-2 KP.1.1 FLiRT & KP.3 Variants
June 14, 2024 07:01 ET
|
Invivyd
Pseudovirus in vitro neutralization data show continued neutralizing activity of VYD222 (pemivibart) against the KP.1.1 FLiRT and KP.3 SARS-CoV-2 variants, virus selections representative of current...
Medicare Issues Final Coverage Determination for kidneyintelX.dkd
June 14, 2024 07:00 ET
|
Renalytix plc
LONDON and NEW YORK, June 14, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that on June 13, 2024 Medicare issued a final Local Coverage Determination ("LCD")...
Ragnarok Online Official Launching in China on June 28, 2024
June 14, 2024 07:00 ET
|
GRAVITY Co., Ltd.
Seoul, South Korea, June 14, 2024 (GLOBE NEWSWIRE) -- GRAVITY Co., Ltd. (NasdaqGM: GRVY) (“Gravity” or “Company”), a developer and publisher of online and mobile games, announces that Ragnarok...
Correction: 仙境传说：破晓 (Ragnarok: Dawn, Tentative English Title) Received an ISBN from the Chinese Government
June 14, 2024 07:00 ET
|
GRAVITY Co., Ltd.
Seoul, South Korea, June 14, 2024 (GLOBE NEWSWIRE) -- GRAVITY Co., Ltd. (NasdaqGM: GRVY) (“Gravity” or “Company”), a developer and publisher of online and mobile games, announced that 仙境传说：破晓...
Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
June 14, 2024 07:00 ET
|
Kymera Therapeutics, Inc.
KT-333 demonstrated initial clinical proof of concept across multiple hematological malignancies, including complete responses in two patients with Hodgkin’s lymphoma Robust STAT3 knockdown and...
Tilray Beverages Announces Campaign to Raise Awareness for Men’s Health
June 14, 2024 07:00 ET
|
Tilray Brands, Inc.
With this campaign and the partnerships involved, Tilray hopes to encourage more men to take an active role in their health and well-being.
Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at European Hematology Association Congress
June 14, 2024 07:00 ET
|
Bio-Path Holdings, Inc.
HOUSTON, June 14, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to...
Chicago Atlantic Real Estate Finance Declares Common Stock Dividend of $0.47 for the Second Quarter of 2024
June 14, 2024 07:00 ET
|
Chicago Atlantic Real Estate Finance, Inc.
CHICAGO, June 14, 2024 (GLOBE NEWSWIRE) -- Chicago Atlantic Real Estate Finance, Inc. (NASDAQ: REFI), a commercial mortgage real estate investment trust, announced that its board of directors has...
TScan Therapeutics Announces Updates to its Board of Directors
June 14, 2024 07:00 ET
|
TScan Therapeutics, Inc.
Garry A. Nicholson, an experienced executive with regulatory and commercial expertise, joins the Board of Directors Timothy Barberich retires as Chair; Stephen Biggar, M.D., Ph.D. assumes the role...
Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress
June 14, 2024 07:00 ET
|
Autolus Therapeutics plc
Autolus Therapeutics to Present Three Clinical Data Updates on obe-cel at EHA